1. Scrip
  2. >>Business

Troubled Immunocore Reawakens With New $130m Funding

Company Diversifies Into Hepatitis B

 
• By Andrew McConaghie

After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?

OXFORD, ENGLAND - JANUARY 25: A view on the streets in Oxford, England on 25 January, 2018
The Oxford, UK-headquartered company needs to generate proof of concept data for its T-cell receptor immunotherapy

Five years ago, Immunocore Ltd. broke a European biotech fundraising record when it raised a hefty $320m in its debut funding round, and looked set to be a real contender among emerging immunotherapy companies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.